source
- Merck's dealmaker warns of increased M&A activity as Keytruda patent expiresMerck's chief M&A officer says the company expects a surge in deal flow as the patent for its flagship immunotherapy, Keytruda, approaches expiration. The leadership has been pursuing acquisitions…
- Superluminal Medicines raises $60 million to advance AI-designed MC4R drug for rare obesity formsSuperluminal Medicines, an AI-driven drug discovery startup, announced a $60 million financing round aimed at moving its first candidate toward clinical testing. The candidate targets the MC4R G p…